Protection of vaccination versus hybrid immunity against infection with COVID-19 Omicron variants among Health-Care Workers.
COVID-19
Health-Care Workers (HCWs)
Hybrid immunity
Infection rate
Vaccine
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
28 11 2022
28 11 2022
Historique:
received:
30
07
2022
revised:
07
09
2022
accepted:
08
09
2022
pubmed:
24
9
2022
medline:
23
11
2022
entrez:
23
9
2022
Statut:
ppublish
Résumé
The Omicron COVID-19 variants BA.1* and BA.2* evade immune system leading to increased transmissibility and breakthrough infections. We aim to test the hypothesis that immunity achieved post COVID-19 infection combined with vaccination (hybrid immunity), is more effective against Omicron infection than vaccination alone in a health-care setting. Data on regular pre-emptive PCR testing from all Health-Care Workers (HCWs) at Laiko University Hospital from 29th December 2020, date on which the national COVID-19 immunization program began in Greece, until 24th May 2022, were retrospectively collected and recorded. The infection rate was calculated after December 21st, 2021, when Omicron was the predominant circulating variant in Greece, as the total number of infections (positive PCR COVID-19 test regardless of symptoms) divided by the total person-months at risk. Of 1,305 vaccinated HCWs who were included in the analysis [median age of 47 (IQR: 36, 56) years, 66.7 % women], 13 % and 87 % had received 2 or 3 vaccine doses (full and booster vaccination), respectively. A COVID-19 infection had occurred in 135 of 1,305 of participants prior to Omicron predominance. Of those 135 HCWs with hybrid immunity only 13 (9.6 %) were re-infected. Of the 154 and 1,016 HCWs with full and booster vaccination-induced immunity, respectively, 71 (46.1 %, infection rate 13.4/100 person-months) and 448 (44.1 %, infection rate 12.2/100 person-months) were infected during the follow up period. No association between gender or age and COVID-19 infection was found and none of the participants had a severe infection or died. Hybrid immunity confers higher protection by almost 5-fold compared to full or booster vaccination for COVID-19 infection with the Omicron variant among HCWs who are at high risk of exposure. This may inform public health policies on how to achieve optimal immunity in terms of the timing and mode of vaccination.
Sections du résumé
BACKGROUND AIM
The Omicron COVID-19 variants BA.1* and BA.2* evade immune system leading to increased transmissibility and breakthrough infections. We aim to test the hypothesis that immunity achieved post COVID-19 infection combined with vaccination (hybrid immunity), is more effective against Omicron infection than vaccination alone in a health-care setting.
METHODS
Data on regular pre-emptive PCR testing from all Health-Care Workers (HCWs) at Laiko University Hospital from 29th December 2020, date on which the national COVID-19 immunization program began in Greece, until 24th May 2022, were retrospectively collected and recorded. The infection rate was calculated after December 21st, 2021, when Omicron was the predominant circulating variant in Greece, as the total number of infections (positive PCR COVID-19 test regardless of symptoms) divided by the total person-months at risk.
RESULTS
Of 1,305 vaccinated HCWs who were included in the analysis [median age of 47 (IQR: 36, 56) years, 66.7 % women], 13 % and 87 % had received 2 or 3 vaccine doses (full and booster vaccination), respectively. A COVID-19 infection had occurred in 135 of 1,305 of participants prior to Omicron predominance. Of those 135 HCWs with hybrid immunity only 13 (9.6 %) were re-infected. Of the 154 and 1,016 HCWs with full and booster vaccination-induced immunity, respectively, 71 (46.1 %, infection rate 13.4/100 person-months) and 448 (44.1 %, infection rate 12.2/100 person-months) were infected during the follow up period. No association between gender or age and COVID-19 infection was found and none of the participants had a severe infection or died.
CONCLUSIONS
Hybrid immunity confers higher protection by almost 5-fold compared to full or booster vaccination for COVID-19 infection with the Omicron variant among HCWs who are at high risk of exposure. This may inform public health policies on how to achieve optimal immunity in terms of the timing and mode of vaccination.
Identifiants
pubmed: 36150972
pii: S0264-410X(22)01150-1
doi: 10.1016/j.vaccine.2022.09.042
pmc: PMC9482842
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7195-7200Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
N Engl J Med. 2022 Mar 31;386(13):1288-1290
pubmed: 35139269
PLoS Med. 2021 Dec 16;18(12):e1003879
pubmed: 34914711
Clin Infect Dis. 2022 Aug 24;75(1):e201-e207
pubmed: 34791108
Clin Infect Dis. 2022 Aug 24;75(1):e185-e190
pubmed: 34864907
Nat Med. 2023 Jan 2;:
pubmed: 36593393
Science. 2021 Feb 5;371(6529):
pubmed: 33408181
N Engl J Med. 2021 Dec 30;385(27):2585-2586
pubmed: 34910864
N Engl J Med. 2022 Jan 27;386(4):340-350
pubmed: 35021002
N Engl J Med. 2022 Mar 17;386(11):1091-1093
pubmed: 35081294
N Engl J Med. 2021 Dec 9;385(24):e83
pubmed: 34614327
Science. 2021 Dec 03;374(6572):abm0829
pubmed: 34648302
J Infect Dis. 2022 Oct 17;226(8):1385-1390
pubmed: 35482442
Clin Infect Dis. 2020 Apr 27;:
pubmed: 32338708
J Med Virol. 2022 Oct;94(10):4780-4791
pubmed: 35680610
Viruses. 2021 Dec 24;14(1):
pubmed: 35062230
Cell. 2022 Feb 3;185(3):467-484.e15
pubmed: 35081335
N Engl J Med. 2022 Apr 21;386(16):1532-1546
pubmed: 35249272
N Engl J Med. 2022 May 12;386(19):1855-1857
pubmed: 35385628
Nat Commun. 2022 Jun 2;13(1):3082
pubmed: 35654888
N Engl J Med. 2022 Feb 24;386(8):799-800
pubmed: 35045222
JAMA Netw Open. 2022 Sep 1;5(9):e2232760
pubmed: 36136332
J Travel Med. 2022 Dec 27;29(8):
pubmed: 36179099
N Engl J Med. 2022 Jul 7;387(1):21-34
pubmed: 35704396